Answer
Sotatercept traps excess Activin-A and other activin receptor type IIA ligands, inhibiting activin signalling and rebalancing pro-proliferative and anti-proliferative signalling to modulate vascular cell proliferation in pulmonary arterial hypertension.
Sources for this answer
- Winrevair 45 mg powder and solvent for solution for injectionMerck Sharp & Dohme (UK) Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 6Document updated
Sources checked